<DOC>
	<DOCNO>NCT00634933</DOCNO>
	<brief_summary>This study evaluate efficacy safety two dose regimen compound know TRU-015 combination methotrexate ( MTX ) patient active rheumatoid arthritis .</brief_summary>
	<brief_title>Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Clinical diagnosis active seropositive rheumatoid arthritis stable dose methotrexate ( 7.525 mg weekly ) least 12 week without history antiTNF use . Any prior use rituximab B cell deplete agent . Any significant health problem rheumatoid arthritis Clinically significant laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>active</keyword>
	<keyword>rheumatoid</keyword>
	<keyword>arthritis</keyword>
	<keyword>anti CD20</keyword>
</DOC>